Gothenburg, Sweden – Denator AB announced today that the company has signed an exclusive distribution agreement for the company’s heat inactivation technology, Stabilizor T1, covering the Japanese market with a leading distributor of scientific and laboratory equipment, AMR Inc.

Under terms of the agreement, AMR Inc will be the exclusive distributor in Japan for the sale, marketing and service of Denator’s Stabilizor system, and all related consumables. AMR Inc. has already sold and delivered the Stabilizor system to important research facilities in Japan such as the Tohoku University where the system is utilized in studies on the clinical application of transplantation of islets of Langerhans.

AMR will present the Stabilizor technology at the annual JHUPO conference in Tokyo in the end of July. Dr. Per Andrén from Uppsala University, Sweden, a current customers of the Stabilizor system, will give a speech at the conference on his research results on endogenous peptides using the Stabilizor system.

Mr. Bando, Chief Strategic Officer at AMR Inc says: “We provide novel proteomic – and biomarker analysis platforms including sample preparation and LC/MS systems for clinical samples such as tissue, blood and other body fluids. Embedding the Stabilizor system into our analysis platform provides an ultimate total solution for the clinical proteomics and peptidomics area. This solution also evolves to neuroscience in brain and epigenetics where the studying post-translational modifications of proteins are of high interest. We believe that Denator’s technology is significantly important for any downstream analysis and are pleased to have an opportunity to distribute this technology and develop a total solution with Denator AB.”

Olof Sköld, CEO at Denator, stated: “We are delighted to be partnering with AMR Inc. As a leading, well-respected distributor of medical devices in Japan, we believe that AMR Inc is well positioned to drive market adoption in this important market arena. We look forward to developing a mutually beneficial relationship with AMR Inc.”

About AMR Inc

For 24 years, AMR Inc has been providing solutions for LC/MS and GC/MS analysis to the pharmaceutical, biotechnological and environmental fields. AMR’s solution-oriented business model encourages the collaboration with academic and industry parties which benefit all participating parties. AMR’s analysis platform covers most of functional molecules such as protein, lipid, oligosaccharides and RNA. The technology platform bridges between analysis and clinical fields and contributes to the newly established clinical biomarker initiative in Japan and has resulted in the publication of the white paper “Developments for a Growing Japanese Patient Population: Facilitating New Technologies for Future Health Care”. For more information visit: www.amr-inc.co.jp

About Denator

Denator develops and sells products that stabilize biological tissues and fluids from the moment of sampling. Stabilization and standardization of sampling processes upstream significantly enhances the quality of data obtained from analytical techniques used downstream. In proteomic and peptidomic investigations, enhanced data quality increases the reliability of data interpretation and can reveal novel proteins and peptides that would be lost or undetectable when using conventional preparation techniques. Based upon the company’s proprietary heat-inactivation technology platform, Denator is developing solutions that enable scientists to stop sample degradation instantly and maintain the stability of sample components throughout the analytical workflow. Established in 2004, Denator is headquartered at the Biotech Center in Gothenburg, Sweden.

For more information visit: www.denator.com

Stabilizor is a trademark of Denator AB.